The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.
Stefano Luminari
No relevant relationships to disclose
Alessandra Dondi
No relevant relationships to disclose
Luigi Marcheselli
No relevant relationships to disclose
Giuseppe Rossi
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Mundipharma; Roche
Carola Boccomini
No relevant relationships to disclose
Annalisa Chiarenza
No relevant relationships to disclose
Luigi Rigacci
No relevant relationships to disclose
Francesco Merli
Consultant or Advisory Role - Roche
Honoraria - Roche
Giovanni Bertoldero
No relevant relationships to disclose
Alessandro Levis
Employment or Leadership Position - SS Antonio e Biagio Hospital, Alessandria (U)
Andres J. Ferreri
No relevant relationships to disclose
Daniele Vallisa
No relevant relationships to disclose
Maria Christina Cox
No relevant relationships to disclose
Monica Balzarotti
No relevant relationships to disclose
Massimiliano Salati
No relevant relationships to disclose
Massimo Federico
No relevant relationships to disclose